Before accessing the site, please choose from the following options.
Executive Director | 13 years industry experience
Executive Director 13 years industry experience
Jonathan Spivak is an Executive Director at Morgan Stanley and a member of the Private Credit team of Morgan Stanley Investment Management (MSIM). Mr. Spivak brings over 13 years of relevant experience. Prior to joining Morgan Stanley in 2017, Mr. Spivak was a Vice President at Tree Line Capital Partners where he was responsible for origination, execution, and asset management of lower middle-market direct lending investments across a wide range of industries. Mr. Spivak also worked at Enhanced Capital Partners, an affiliate of Tree Line, where he held a similar role and served as an Investment Manager of its Small Business Investment Company. Mr. Spivak began his career at Bank of America Merrill Lynch where he was an Analyst and Associate in the Structured Equity Finance group, investing the bank’s balance sheet in various parts of the capital structure. Mr. Spivak holds a B.A. from the University of Pennsylvania and an M.B.A. from the University of Chicago Booth School of Business.
The information on this page is for informational purposes only. It is intended for the benefit of third party issuers and those seeking information about alternatives investment strategies. The information contained herein does not constitute and should not be construed as an offering of advisory services or an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer or solicitation, purchase or sale would be unlawful under the securities, insurance or other laws of such jurisdiction.
All investing involves risks, including a loss of principal. Alternative investments are speculative and involve a high degree of risk. These investments are designed for investors who understand and are willing to accept these risks. Performance may be volatile, and an investor could lose all or a substantial portion of his or her investment.
Please refer to the strategy detail page for important information on the strategy, including additional risk considerations.